107 related articles for article (PubMed ID: 10851740)
1. Environmental radon daughters reveal pathognomonic changes in the brain proteins and lipids in patients with Alzheimer's disease and Parkinson's disease, and cigarette smokers.
Momcilović B; Alkhatib HA; Duerre JA; Cooley MA; Long WM; Harris RT; Lykken GI
Arh Hig Rada Toksikol; 1999 Dec; 50(4):347-69. PubMed ID: 10851740
[TBL] [Abstract][Full Text] [Related]
2. Environmental lead-210 and bismuth-210 accrue selectively in the brain proteins in Alzheimer disease and brain lipids in Parkinson disease.
Momcilović B; Alkhatib HA; Duerre JA; Cooley M; Long WM; Harris TR; Lykken GI
Alzheimer Dis Assoc Disord; 2001; 15(2):106-15. PubMed ID: 11403330
[TBL] [Abstract][Full Text] [Related]
3. Deposition of Alzheimer's disease amyloid (A4) protein in the cerebral cortex in Parkinson's disease.
Mastaglia FL; Masters CL; Beyreuther K; Kakulas BA
Prog Clin Biol Res; 1989; 317():475-84. PubMed ID: 2690109
[TBL] [Abstract][Full Text] [Related]
4. Cerebral metabolic relationships for selected brain regions in Alzheimer's, Huntington's, and Parkinson's diseases.
Metter EJ; Riege WH; Kameyama M; Kuhl DE; Phelps ME
J Cereb Blood Flow Metab; 1984 Dec; 4(4):500-6. PubMed ID: 6238975
[TBL] [Abstract][Full Text] [Related]
5. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.
Burton EJ; McKeith IG; Burn DJ; Williams ED; O'Brien JT
Brain; 2004 Apr; 127(Pt 4):791-800. PubMed ID: 14749292
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's and Parkinson's diseases: an environmental proteomic point of view.
Demartini DR; Schilling LP; da Costa JC; Carlini CR
J Proteomics; 2014 Jun; 104():24-36. PubMed ID: 24751585
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin immunoreactivity is reduced in Parkinson's disease dementia with Alzheimer's changes.
Beal MF; Mazurek MF; Martin JB
Brain Res; 1986 Nov; 397(2):386-8. PubMed ID: 3801878
[TBL] [Abstract][Full Text] [Related]
8. Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease.
Langston JW; Sastry S; Chan P; Forno LS; Bolin LM; Di Monte DA
Exp Neurol; 1998 Dec; 154(2):684-90. PubMed ID: 9878203
[TBL] [Abstract][Full Text] [Related]
9. Cortical neuropathological and neurochemical substrates of Alzheimer's and Parkinson's diseases.
Perry RH; Perry EK; Smith CJ; Xuereb JH; Irving D; Whitford CA; Candy JM; Cross AJ
J Neural Transm Suppl; 1987; 24():131-6. PubMed ID: 2824687
[TBL] [Abstract][Full Text] [Related]
10. Cortical somatostatinergic system not affected in Alzheimer's and Parkinson's diseases.
Whitford C; Candy J; Edwardson J; Perry R
J Neurol Sci; 1988 Aug; 86(1):13-8. PubMed ID: 2902199
[TBL] [Abstract][Full Text] [Related]
11. Cortical muscarinic receptors in demented patients with Alzheimer's disease or Parkinson's disease.
Lange KW; Wells FR; Rossor MN; Jenner P; Marsden CD
Br J Pharmacol; 1989 Dec; 98 Suppl():817P. PubMed ID: 2611524
[No Abstract] [Full Text] [Related]
12. Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type.
Söderberg M; Edlund C; Alafuzoff I; Kristensson K; Dallner G
J Neurochem; 1992 Nov; 59(5):1646-53. PubMed ID: 1402910
[TBL] [Abstract][Full Text] [Related]
13. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.
Ahlskog JE; Uitti RJ; Low PA; Tyce GM; Nickander KK; Petersen RC; Kokmen E
Mov Disord; 1995 Sep; 10(5):566-73. PubMed ID: 8552107
[TBL] [Abstract][Full Text] [Related]
14. Distribution of VGF peptides in the human cortex and their selective changes in Parkinson's and Alzheimer's diseases.
Cocco C; D'Amato F; Noli B; Ledda A; Brancia C; Bongioanni P; Ferri GL
J Anat; 2010 Dec; 217(6):683-93. PubMed ID: 21039478
[TBL] [Abstract][Full Text] [Related]
15. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.
Pletnikova O; West N; Lee MK; Rudow GL; Skolasky RL; Dawson TM; Marsh L; Troncoso JC
Neurobiol Aging; 2005; 26(8):1183-92. PubMed ID: 15917102
[TBL] [Abstract][Full Text] [Related]
16. Natural distribution of environmental radon daughters in the different brain areas of an Alzheimer disease victim.
Momcilović B; Lykken GI; Cooley M
Mol Neurodegener; 2006 Sep; 1():11. PubMed ID: 16965619
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin and neuropeptide Y immunoreactivity in Parkinson's disease dementia with Alzheimer's changes.
Beal MF; Clevens RA; Mazurek MF
Synapse; 1988; 2(4):463-7. PubMed ID: 2903567
[TBL] [Abstract][Full Text] [Related]
18. [Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation].
Dubois B; Hauw JJ; Ruberg M; Serdaru M; Javoy-Agid F; Agid Y
Rev Neurol (Paris); 1985; 141(3):184-93. PubMed ID: 4001706
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
20. Neurochemical abnormalities in Alzheimer's disease and Parkinson's disease--a comparative review.
Gsell W; Strein I; Krause U; Riederer P
J Neural Transm Suppl; 1997; 51():145-59. PubMed ID: 9470135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
